tuneTypical Dose
5-7 g/day is the range used in most clinical trials and supported by the strongest evidence
Fiber Supplement
Partially Hydrolyzed Guar Gum (PHGG)
Partially hydrolyzed guar gum (Cyamopsis tetragonoloba)
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Some users notice stool changes within the first week. The IBS bloating evidence is based on 12-week protocols, with significant separation from placebo emerging over the treatment period. Prebiotic microbiota shifts are detectable within 3 weeks.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
PHGG is a soluble, non-gelling prebiotic fiber best supported for IBS-related bloating, stool normalization, and as a prebiotic adjunct, with uniquely low GI side effects compared with other fiber supplements.
Partially hydrolyzed guar gum is an enzymatically processed soluble fiber that dissolves completely, does not gel, and ferments gradually in the colon. Human trials support its use for reducing IBS-associated bloating, normalizing stool form in both constipation and diarrhea patterns, and acting as a prebiotic that promotes Bifidobacterium and butyrate production. A notable trial also supports its role as an adjunct to rifaximin for SIBO eradication. The tolerability advantage is arguably its most practically important feature, because PHGG causes substantially less bloating and gas than psyllium, wheat bran, and most other fiber supplements. The evidence base consists of multiple small-to-moderate RCTs with consistent direction but lacks a large-scale meta-analysis or definitive pivotal trial.
PHGG is a soluble, non-gelling prebiotic fiber produced by enzymatic hydrolysis of guar gum. It reaches the colon intact and is fermented gradually by resident bacteria, producing short-chain fatty acids (especially butyrate). It selectively promotes Bifidobacterium and butyrate-producing bacteria, regulates colonic water content bidirectionally to normalize both loose and hard stools, and causes substantially less gas and bloating than other fibers due to its low viscosity and gradual fermentation profile.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Reduced IBS-associated bloating and gas symptoms
- Normalized stool form in both constipation and diarrhea patterns
Secondary Outcomes
- Improved SIBO eradication rate when used as adjunct to rifaximin
- Increased fecal Bifidobacterium abundance and butyrate production
- Superior tolerability and adherence compared with other fiber supplements
Safety
Contraindications and Interactions
Contraindications
- Bowel obstruction or severe gastrointestinal stricturing disease
- Known guar gum allergy
Side effects
- Mild gas or bloating in first few days
- Mild abdominal discomfort during initial use
Interactions
- Time-sensitive oral medications
Avoid if
- Bowel obstruction or severe gastrointestinal stricturing is present
- Known guar gum allergy
- GI symptoms worsen rather than improve after starting PHGG
Evidence
Study-level References
phgg-SRC-001Randomized double-blind placebo-controlled trial
Sourceopen_in_newNiv E, Halak A, Tiommny E, Yanai H, Strul H, Naftali T, Vaisman N. Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome. Nutr Metab (Lond). 2016;13:10. PMID: 26855665.
Population: Adult patients with irritable bowel syndrome diagnosed by Rome III criteria
Dose protocol: 6 g/day PHGG versus placebo for 12 weeks in IBS patients (Rome III)
Key findings: Significant reduction in bloating and bloating-plus-gas scores versus placebo. Benefit persisted 4 weeks after stopping. No significant improvement in overall IBS severity or quality of life versus placebo.
Notes: The strongest placebo-controlled evidence for PHGG in IBS. Important because it pins the benefit to bloating specifically rather than broad symptom relief.
Paper content
This double-blind placebo-controlled trial found that 12 weeks of 6 g/day PHGG significantly improved bloating and combined bloating-plus-gas scores in IBS patients compared with placebo. The bloating benefit persisted for at least 4 weeks after the last PHGG dose. However, PHGG did not significantly improve overall IBS severity scores or quality of life measures compared with placebo. The study supports PHGG specifically for IBS-associated bloating rather than as a broad IBS symptom reliever.
phgg-SRC-002Multicenter randomized open-label trial
Sourceopen_in_newParisi GC, Zilli M, Miani MP, et al. High-fiber diet supplementation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial comparison between wheat bran diet and partially hydrolyzed guar gum (PHGG). Dig Dis Sci. 2002;47(8):1697-704. PMID: 12184518.
Population: Adult patients with irritable bowel syndrome (diarrhea-predominant, constipation-predominant, or alternating bowel habits)
Dose protocol: PHGG 5 g/day versus wheat bran 30 g/day for 12 weeks in 188 IBS patients
Key findings: PHGG achieved 60% success rate versus 40% for wheat bran on intention-to-treat. Nearly half of bran users crossed over to PHGG due to intolerance. Both fibers improved symptoms per-protocol.
Notes: The tolerability story is the most important finding. Open-label design limits efficacy conclusions but the adherence data is highly relevant for real-world fiber selection.
Paper content
This multicenter randomized trial compared PHGG 5 g/day with wheat bran 30 g/day in 188 IBS patients over 12 weeks. Per-protocol analysis showed both fibers improved pain and bowel habits, but intention-to-treat analysis found PHGG achieved a significantly higher success rate (60% vs 40%) largely because PHGG was far better tolerated. Nearly half the wheat bran group crossed over to PHGG, while only about 11% of PHGG users switched to bran. The study demonstrated that PHGG is at least as effective as wheat bran for IBS symptom management while being substantially better tolerated, which translates to better real-world adherence and outcomes.
phgg-SRC-003Randomized controlled trial
Sourceopen_in_newFurnari M, Parodi A, Gemignani L, et al. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2010;32(8):1000-6. PMID: 20937045.
Population: Consecutive adult patients with glucose breath test-confirmed small intestinal bacterial overgrowth (SIBO)
Dose protocol: PHGG 5 g/day plus rifaximin 1200 mg/day versus rifaximin alone for 10 days in SIBO patients
Key findings: Combination achieved 87.1% SIBO eradication versus 62.1% with rifaximin alone (p=0.017). Clinical improvement was high in both groups among those who achieved eradication.
Notes: Well-cited in the gastroenterology literature. Mechanistic rationale is sound (prebiotic substrate activates dormant bacteria, increasing antibiotic susceptibility). Needs replication.
Paper content
This randomized trial demonstrated that adding 5 g/day PHGG to rifaximin 1200 mg/day for 10 days significantly improved SIBO eradication rates compared with rifaximin alone. The combination achieved an 87.1% eradication rate (per-protocol) versus 62.1% with rifaximin alone. The proposed mechanism is that PHGG acts as a prebiotic substrate that draws bacteria into a metabolically active state, making them more susceptible to rifaximin. Clinical improvement rates were high in both groups among those who achieved eradication.
phgg-SRC-004Randomized double-blind placebo-controlled parallel-group trial
Sourceopen_in_newYasukawa Z, Inoue R, Ozeki M, Okubo T, Takagi T, Honda A, Naito Y. Effect of Repeated Consumption of Partially Hydrolyzed Guar Gum on Fecal Characteristics and Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled, and Parallel-Group Clinical Trial. Nutrients. 2019;11(9):2170. PMID: 31509971.
Population: Healthy volunteers with tendency toward loose stools or irregular bowel habits
Dose protocol: 5 g/day PHGG versus placebo for 3 weeks in 44 healthy volunteers with loose stool tendency
Key findings: Increased Bifidobacterium abundance, raised short-chain fatty acid concentrations including butyrate, and improved stool consistency in subjects with loose stools.
Notes: Confirms prebiotic mechanism in humans. Small sample and healthy-volunteer design limit clinical extrapolation to IBS populations.
Paper content
This double-blind placebo-controlled trial demonstrated that 3 weeks of daily PHGG consumption improved stool consistency in subjects with loose stools, increased fecal Bifidobacterium abundance, and raised short-chain fatty acid concentrations including butyrate. The study supports the dual-direction stool-normalizing property of PHGG and provides mechanistic evidence for its prebiotic activity in humans. PHGG selectively promoted beneficial gut bacteria and increased fermentation-derived metabolites associated with colonic health.
phgg-SRC-005Multicenter randomized open-label trial.
Sourceopen_in_newParisi G, Bottona E, Carrara M, et al. Treatment effects of partially hydrolyzed guar gum on symptoms and quality of life of patients with irritable bowel syndrome. A multicenter randomized open trial. Dig Dis Sci. 2005;50(6):1107-1112. doi:10.1007/s10620-005-2713-7. PMID:15986863.
Population: Adults with irritable bowel syndrome.
Dose protocol: PHGG 5 g/day versus 10 g/day for 12 weeks in adults with IBS, with follow-up after stopping treatment.
Key findings: Both dose groups improved GI symptoms, quality of life, and psychological distress during treatment, with partial loss of benefit after discontinuation.
Notes: Helpful supportive study because it broadens the signal beyond bloating alone, but it was open-label and compared two active doses rather than placebo.
Paper content
This multicenter randomized open-label PHGG trial compared 5 g/day and 10 g/day dosing for 12 weeks in adults with IBS. Both dose groups improved gastrointestinal symptoms, quality of life, and psychological distress relative to baseline, but the effect attenuated after treatment stopped. The trial is useful because it supports a broader symptom-improvement signal and suggests PHGG can help beyond a single bloating endpoint, but the absence of placebo and the dose-comparison design limit causal confidence. It fits best as supportive open-label evidence rather than definitive proof of efficacy.
phgg-SRC-006Open-label intervention study.
Sourceopen_in_newRusso L, Andreozzi P, Zito FP, et al. Partially hydrolyzed guar gum in the treatment of irritable bowel syndrome with constipation: effects of gender, age, and body mass index. Saudi J Gastroenterol. 2015;21(2):104-110. doi:10.4103/1319-3767.153835. PMID:25843197.
Population: Adults with constipation-predominant irritable bowel syndrome.
Dose protocol: Four-week PHGG intervention after a 2-week run-in in constipation-predominant IBS.
Key findings: Improved stool form, colonic transit time, laxative reliance, and several symptom scores, with response differences across sex, age, and BMI subgroups.
Notes: Useful IBS-C support study. The subgroup findings are interesting, but the non-blinded design keeps confidence modest.
Paper content
This IBS-C study evaluated PHGG over 4 weeks after a short run-in period and found significant improvements in symptom scores, stool form, colonic transit time, and reduced laxative or enema use relative to baseline. The subgroup analyses suggested that response patterns varied by sex, age, and BMI, which is useful nuance for constipation-predominant IBS even though the study was not blinded or placebo-controlled. The paper strengthens the practical constipation narrative for PHGG, but its design means it should remain supportive evidence rather than a major driver of confidence.
phgg-SRC-007Randomized, double-blind, placebo-controlled, parallel-group trial.
Sourceopen_in_newAbe A, Kapoor MP, Morishima S, Ozeki M, Sato M, Takara T, Naito Y. Effectiveness of Partially Hydrolyzed Guar Gum on Cognitive Function and Sleep Efficiency in Healthy Elderly Subjects. Nutrients. 2024;16(8):1211. doi:10.3390/nu16081211. PMID:38674901.
Population: Healthy elderly subjects.
Dose protocol: 5 g/day PHGG versus placebo for 12 weeks in healthy elderly subjects
Key findings: Visual memory scores and sleepiness on rising significantly improved in the PHGG group compared to placebo. First RCT linking PHGG to cognitive outcomes in an elderly population.
Notes: Extends PHGG benefits beyond gut health into cognitive and sleep domains. Manufacturer-affiliated authors. Gut-brain axis mediation is plausible but not directly measured.
Paper content
This double-blind, placebo-controlled RCT tested 5 g/day of PHGG for 12 weeks in healthy elderly subjects. The PHGG group showed significant improvements in visual memory scores and reduced sleepiness on rising compared to placebo. These findings extend the known benefits of PHGG beyond gut health into cognitive and sleep domains, possibly mediated through the gut-brain axis via increased short-chain fatty acid production. The study is notable because it is the first RCT to link PHGG to cognitive outcomes in an elderly population.
phgg-SRC-008Randomized, placebo-controlled, double-blind trial.
Sourceopen_in_newSakai S, Kamada Y, Takano H, Ichikawa M, Kurimoto M, Katsuyama HK, Nishihira J, Sasaki M. Continuous partially hydrolyzed guar gum intake reduces cold-like symptoms: a randomized, placebo-controlled, double-blinded trial in healthy adults. Eur Rev Med Pharmacol Sci. 2022;26(14):5154-5163. doi:10.26355/eurrev_202207_29304. PMID:35916813.
Population: Healthy Japanese adults.
Dose protocol: 5.2 g/day PHGG versus placebo for 12 weeks in 96 healthy Japanese adults
Key findings: PHGG group had significantly more symptom-free days and lower cold-like symptom severity. Fecal propionic acid and butyric acid increased significantly.
Notes: Suggests PHGG may support immune function through prebiotic-mediated SCFA production. Single trial in a specific population, but double-blind design is robust.
Paper content
This double-blind, placebo-controlled RCT tested 5.2 g/day of PHGG for 12 weeks in 96 healthy Japanese adults. The PHGG group experienced significantly more symptom-free days and lower cold-like symptom severity. Fecal propionic acid and butyric acid concentrations increased significantly in the PHGG group, consistent with enhanced colonic fermentation. The findings suggest that PHGG may support immune function through prebiotic-mediated short-chain fatty acid production, extending its utility beyond digestive symptom management.